statins, ezetimibe

PreclinicalSmall molecule

KKorea University Anam Hospital

statins, ezetimibe is one of 42 small molecule programs targeting Heart Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart DiseaseActive, not recruiting

Heart DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

55 competitors in Heart Disease

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

3 2

Bayer Aspirin

Bayer

Approved

2 3

Corlanor

Amgen

Approved

1 4

Lorelco

Sanofi

Approved

1 5

Leqvio

Novartis

Approved

1 6

Colcrys

Jazz Pharmaceuticals

Approved

1 7

Savaysa

Daiichi Sankyo

Approved

—8

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 9

Heparin Sodium

BBaxter Healthcare Corporation

Approved

1 10

Pepcid

KKenvue Brands

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

ApprovedActive, not recruiting

Coronary Artery Disease

NCT06767345

Clinical

Trials by Indication[1]

Heart Disease1 trial

Risk Reduction in Coronary Heart Disease

Completed·SSorlandet Hospital HF·N/A·NCT00679237·1,600 enrolled

Coronary Artery Disease1 trial

Comparing the Moderate Intensity STatin With Ezetimibe COmbination TheraPy With High Intensity Statin Monotherapy on Coronary PLAQUE Stabilization

Active, not recruiting·KKorea University Anam Hospital·Approved·NCT06767345·410 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for statins, ezetimibe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — statins, ezetimibe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for statins, ezetimibe. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Korea University Anam Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKorea University Anam Hospital

statins, ezetimibe

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Heart Disease1 trial

Coronary Artery Disease1 trial

References

Drug Info

Quick Facts

Related News